Commercial launch is on-track for ZUSDURI™, the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC); net sales ...

Chief Commercial Officer David Lin reported, “ZUSDURI generated $1.8 million in net product revenue in Q3, and $14 million in Q4, bringing full year 2025 revenue to $15.8 million,” and detailed ...

Urogen Pharma (NASDAQ:URGN) executives used the company’s fiscal 2025 earnings call to highlight early commercial momentum for newly launched Zusduri, continued growth from its established product ...

AI systems are beginning to build and improve themselves. But without a verification layer, trust, safety and accountability ...

Commercial launch is on-track for ZUSDURI, the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC); net sales ...

Stop rules are simple. If Match fails, do not show the output to users or decision makers. If Matter does not improve results ...

Public debate about artificial intelligence in higher education has largely orbited a familiar worry: cheating. Will students use chatbots to write essays? Can instructors tell? Should universities ...

Check out all Craft Anime recipes here, along with the steps for crafting, element details, and mutation multipliers.

When your AI assistant calculates revenue, bonuses, VAT or financial summaries, it isn’t doing math. It’s telling a convincing story about numbers.

With all of the talk about the security risks of AI, one issue that seems to be overlooked is this: the fact that AI systems only function by exposing their most valuable assets — models and data.

Figma's aggressive AI-native feature rollout and integration of external LLMs have driven robust adoption. Click here to find out why FIG stock is a Buy.

Plasma physicist Debbie Callahan, chief strategy officer at Focused Energy, talks to Hamish Johnston about her work in laser fusion research ...